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IMPORTANCE Both primary and secondary forms of childhood glaucoma havemany distinct
causative mechanisms, and in many cases a cause is not immediately clear. The broad
phenotypic spectrum of secondary glaucoma, particularly in individuals with variants in
FOXC1 or PITX2 genes associated with Axenfeld-Rieger syndrome, makes it more difficult to
diagnose patients with milder phenotypes. These cases are occasionally classified and
managed as primary congenital glaucoma.
OBJECTIVE To investigate the prevalence of FOXC1 variants in participants with a suspected
diagnosis of primary congenital glaucoma.
DESIGN, SETTING, AND PARTICIPANTS Australian and Italian cohorts were recruited from
January 1, 2007, throughMarch 1, 2016. Australian individuals were recruited through the
Australian and New Zealand Registry of Advanced Glaucoma and Italian individuals through
the Genetic and Ophthalmology Unit of l’Azienda Socio–Sanitaria Territoriale Grande
Ospedale Metropolitano Niguarda in Milan, Italy. We performed exome sequencing, in
combination with Sanger sequencing andmultiplex ligation-dependent probe amplification,
to detect variants of FOXC1 in individuals with a suspected diagnosis of primary congenital
glaucoma established by their treating specialist. Data analysis was completed from June
2015 to November 2017.
MAIN OUTCOME ANDMEASURES Identification of single-nucleotide and copy number variants
in FOXC1, along with phenotypic characterization of the individuals who carried them.
RESULTS A total of 131 individuals with a suspected diagnosis of primary congenital glaucoma
were included. Themean (SD) age at recruitment in the Australian cohort was 24.3 (18.1)
years; 37 of 84 Australian participants (44.0%) were female, and 71 of 84 (84.5%) were of
European ancestry. Themean (SD) age at recruitment was 22.5 (18.4) years in the Italian
cohort; 21 of 47 Italian participants (44.7%) were female, and 45 of 47 (95.7%) were of
European ancestry. We observed rare, predicted deleterious FOXC1 variants in 8 of 131
participants (6.1%), or 8 of 166 participants (4.8%) when including those explained by
variants in CYP1B1. On reexamination or reinvestigation, all of these individuals had at least
1 detectable ocular and/or systemic feature associated with Axenfeld-Rieger syndrome.
CONCLUSIONS AND RELEVANCE These data highlight the genetic and phenotypic
heterogeneity of childhood glaucoma and support the use of gene panels incorporating
FOXC1 as a diagnostic aid, especially because clinical features of Axenfeld-Rieger syndrome
can be subtle. Further replication of these results will be needed to support the future use of
such panels.
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G laucoma is a heterogeneous group of optic neuropa-thies associated with irreversible visual field loss.1Childhood glaucoma (defined here as glaucoma oc-
curring with an age at onset younger than 18 years)2 is gener-
ally amore severedisease than its adult counterpart, and it of-
ten requires multiple surgical interventions to control high
intraocular pressure (IOP). Causes of childhood glaucoma are
typically classified as primary or secondary2; primary child-
hood glaucoma includes primary congenital glaucoma (PCG)
and juvenileopen-angleglaucoma,while secondarycauses in-
clude Axenfeld-Rieger anomaly (ARA), Peters anomaly, an-
iridia, and ectopia lentis.
Primary congenital glaucoma is the most common non-
syndromic cause of childhood glaucoma and is characterized
by elevated IOP and associated sequelae, including optic disc
cupping, buphthalmos, Haab striae, enlarged corneal diam-
eter, corneal edema, and/or increased axial length. The dis-
easehas anapproximate incidenceof 1:18 500 inGreatBritain3
and 1:30000 inAustralia.4 There is an increased incidence of
PCG in ethnic groups inwhichparental consanguinity ismore
common (such as Pakistani British populations),3 or where
there is a strong founder effect (eg, an incidence of 1:1250
among Romani Slovakian individuals),5,6 which is consistent
with autosomal recessive inheritance.
Axenfeld-Rieger anomaly is a rare condition defined by a
collectionof 1 ormoreocular features, includingposterior em-
bryotoxon, iris stromal hypoplasia, peripheral anterior syn-
echiae (PAS), corectopia, or pseudopolycoria.7 This condition
may also be associated with 1 or more systemic features, in
whichcase it is referred toasAxenfeld-RiegerSyndrome(ARS).
Glaucoma is present in approximately 50% of individuals
with ARS.8
Both primary and secondary childhood glaucomamaybe
associatedwith variants in one of several genes. Cases of PCG
aremost commonly associatedwith autosomal recessivevari-
ants inCYP1B19 or less commonlywithheterozygous variants
of TEK10 orANGPT1.11 Causes of secondary glaucoma include
microspherophakia and/or ectopia lentis associatedwithvari-
ants in LTBP2,12-14 aniridia owing to variants in PAX6,15 Pe-
tersanomalyowing tovariants inPAX6,CYP1B1,PITX2,FOXC1,
or other genes,16 andARAorARSowing tovariation inPITX217
or FOXC1.18
Key phenotypic differences exist between ARS associ-
ated with FOXC1 or PITX2 variants. Cases of ARS associated
with PITX2 typically present with dental and umbilical
anomalies,7,19,20 while sensorineural hearing loss, intellec-
tual disability, and congenital heart defects are more charac-
teristic of patients with variants in FOXC1.21 Facial dysmor-
phism, includingmaxillary hypoplasia, a broad and flat nasal
bridge, telecanthus,orhypertelorism, canbeobserved inboth.
FOXC1-associated ARS typically presents with glaucoma at a
younger age than PITX2-associated ARS, with 23% of FOXC1
carriers diagnosedbefore the ageof 3 years comparedwith 7%
of PITX2 carriers.21
Ocular or systemic features of ARS are not always readily
apparent; posterior embryotoxon, for example, may not al-
ways be visible on slitlamp examination,22 and systemic fea-
turesmaynot be apparent until later in life, if at all. In our pre-
vious study,21 1 FOXC1 carrier displayed systemic features in
the first few years of life, compared with all of the PITX2 car-
riers. These ambiguities, combinedwith the difficulties asso-
ciated with thorough pediatric ophthalmic examination (of-
ten requiring general anesthesia), can occasionally lead to a
diagnosis of PCG. Overall, this suggests that FOXC1 variants
might account for suspected diagnoses of PCG. In this study,
we used sequencing and copy-number analysis of the FOXC1
locus to refine the diagnostic classification of 166 partici-
pants with a suspected diagnosis of PCG.
Methods
Participant Recruitment
Australian individuals with PCG and their families were re-
cruited through the Australian and New Zealand Registry of
AdvancedGlaucoma(ANZRAG),23with Italian individualswith
PCG and their families recruited at the Genetic and Ophthal-
mology Unit of l’Azienda Socio–Sanitaria Territoriale Grande
OspedaleMetropolitanoNiguarda (Milan, Italy). Patientswith
a suspected diagnosis of PCGmade by their treating ophthal-
mologistwere includedfromtheAustraliancohort (n = 84)and
the Italian cohort (n = 47). Control individuals (n = 106) were
confirmed to not have glaucoma or anterior segment dysgen-
esis on ocular examination.
Informedwritten consent was obtained from participants
or their guardians, and blood or saliva samples collected along
with clinical details fromthe referringophthalmologist. Ethics
approval was obtained from the Southern Adelaide Clinical
HumanResearchEthicsCommittee (Australia), theMedicalFac-
ulty of the University of Erlangen-Nürnberg (Germany), and
l’Azienda Socio–Sanitaria Territoriale Grande Metropolitano
Niguarda Hospital (Italy).
Sequencing
Forexomesequencing,genomicDNAwasextractedfromblood
samples using a QIAamp Blood Maxi Kit (Qiagen) and sub-
jected to exome capture (Agilent SureSelect, version 4).
Saliva samples were collected with Oragene DNA Self-
Collection Kits (DNAGenotek Inc) and DNA extracted per the
Key Points
Question What is the prevalence of FOXC1 variants, which are
associated with Axenfeld-Rieger syndrome and secondary
glaucoma, in individuals with a suspected diagnosis of primary
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Findings Among a cohort of 166 Australian and Italian affected
individuals, predicted deleterious FOXC1 variants were observed
in approximately 1 in 20 participants. On reexamination or
reinvestigation, all of these individuals had at least 1 detectable
ocular and/or systemic feature associated with Axenfeld-Rieger
syndrome.
Meaning These findings highlight the genetic and phenotypic
heterogeneity of childhood glaucoma and suggest that FOXC1
sequencingmay aid its diagnosis.
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manufacturer’s instructions. All paired-end librarieswere se-
quenced on a HiSeq 2000 (Illumina), with the exception of a
single Italian trio that was sequenced on the SOLiD 4 System
(Life Technologies). Reads were mapped to the human refer-
ence genome (hg19) using Burrows-Wheeler Aligner (http://
bio-bwa.sourceforge.net), andduplicatesmarkedandremoved
withPicardTools (Broad Institute). Variantswere calledusing
Sequence Alignment/Map (SAM) tools and annotated with
ANNOVAR (http://annovar.openbioinformatics.org/en/
latest/). All variants were annotated using the genome
aggregationdatabase (gnomAD)variantdatabase (release2.0.2;
http://gnomad.broadinstitute.org), andwithSorting Intolerant
From Tolerant (SIFT) and PolyPhen-2 scores. FOXC1 variants
were annotatedagainst the consensus transcript (NM_001453.
2) and protein (NP_001444.2) sequences. For capillary
sequencing,genomicDNAwaspreparedfrom200μLofvenous
blood collected in EDTA-coated tubes and extracted using an
Illustra Blood Genomic Prep MiniSpin kit (GE Healthcare), or
Flexi-Gene kit (Qiagen), according to the manufacturer’s
instructions. Primers for amplificationofFOXC1genomicDNA
are available on request. All variants are publicly available at
the ClinVar database (accession numbers SCV000494251,
SCV000494255, SCV000494257, SCV000494258,
SCV000494261, SCV000494267, SCV000693681, and
SCV000693680).
Exome Copy Number Variant Analysis
Coverage depth across the FOXC1 locus and neighboring loci
was extracted from exome Binary Alignment/Map files using
SAMtools. For copy number variations analysis using Copy
Number Inference From Exome Reads (CoNIFER; version
0.2.2), the same interval was analyzed in 343 contemporane-
ously sequenced exomes using the parameters singular value
decomposition (SVD) version5 and the z score of the readsper
kilobase per million mapped reads (ZRPKM) version 1.5.
Multiplex Ligation-Dependent Probe Amplification
FOXC1 copy number was measured by multiplex ligation-
dependentprobeamplification (MLPA)using theSALSAMLPA
P054-B2 FOXL2-TWIST1 probemix (MRC Holland) according
to themanufacturer’s instructions.Ligationsites for theFOXC1
probes (FOXC1-A [02561-L02029]) and FOXC1-B [02562-
L02030]) were located at 925 base pairs (bp) and 1532 bp, re-
spectively, of NM_001453.2. The copy number present in the
original DNA specimenwasdetermined from the relative am-
plitudeofeachampliconproductdetectedusing theABI3130xl
Genetic Analyzer, and data analyzed using Peak Scanner ver-
sion 2.0 (ThermoFisher Scientific).
Results
Genetic Analysis
In theAustraliancohort,mean (SD)ageat recruitmentwas24.3
(18.1) years; 37of84 (44.0%)were female, and71of84 (84.5%)
wereofEuropeanancestry. In the Italiancohort, themean (SD)
age at recruitmentwas 22.5 (18.4) years; 21 of 47 (44.7%)were
female, and 45 of 47 (95.7%) were of European ancestry.
From a collection of Australian individuals with a sus-
pecteddiagnosis of PCG,we selected65probandswhose con-
ditionswerenot explainedbyhomozygous or compoundhet-
erozygous variants of CYP1B1. All 65 individuals underwent
exome sequencing, and variation at the FOXC1 locus was ex-
amined.RareFOXC1variants predicted to bedeleteriouswere
identified in 2 of the 65 individuals, including frameshift de-
letion c.718_719delCT, p.(Leu240ValfsTer65) in participant
PCG128 andmissense variant c.269C>A, p.(Ala90Asp) in par-
ticipant PCG140 (Figure 1A).
By examining the depth of coverage across the FOXC1 lo-
cus, a large deletion spanning FOXC1 and the neighboring
GMDS genewas identified in participant PCG029 (Figure 1B).
It also became clear that portions of FOXC1 were poorly cov-
eredbyexomecaptureandsequencing (Figure 1BandC), likely
becauseofahighguanine-cytosinecontent.24ThesingleFOXC1
coding exon was therefore resequenced in all 65 proband in-
dividuals by capillary sequencing, alongside an additional 19
PCGprobandswhoseconditionswerenotexplainedbyCYP1B1
variants.Multiplex ligation-dependentprobeamplificationwas
performed on 73 of these individuals to detect FOXC1 copy
numbervariations (bothgains and losses).Anadditional 3 rare
protein-coding variantswere identified by capillary sequenc-
ing, includingnonsensevariantc.487G>T,p.(Glu163Ter) inpar-
ticipant PCG033,missense variant c.457A>C, p.(Thr153Pro) in
participant PCG057, and frameshift deletion c.100_109del10,
p.(Gly34ThrfsTer8) inparticipant PCG125 (Figure 1C). All vari-
ants and deletions identified by exome sequencingwere vali-
dated by capillary sequencing or MLPA (Figure 1D).
Noneofthe6variantsidentifiedintheAustraliancohortwere
present in 106controls exomes sequenced inparallel, norwere
they reported in thegnomADvariant collection. In total,FOXC1
variants accounted for6of84participants (7.1%) in theAustra-
liancohortor6of 104participants (5.8%)when including those
whose conditionswere explained by variants inCYP1B1.
In a separate cohort of Italian participants with sus-
pected PCG, 22 family trios whose conditions were not ex-
plained by variants in CYP1B1 underwent exome sequencing.
FOXC1was also covered by capillary sequencing in all 22 pro-
bands plus an additional 25 Italian probands inwhichCYP1B1
variants had been excluded by capillary sequencing. Pre-
dictedpathogenicFOXC1variantswere identified in2of 47 in-
dividuals (4.2%) in the Italian cohort. De novo in-frame dele-
tion c.409_411del, p.(Val137del) in participant PCG402-IT,
identified by exome sequencing, has previously been
described.25A seconddenovo frameshift deletion, c.349delG,
p.(Asp117ThrfsTer64),was identified inparticipantPCG297-IT
by capillary sequencing. Neither variant was present in 680
European control participants without glaucoma, and nei-
therwas reported ingnomAD.When includingpatientswhose
conditions were explained by variants in CYP1B1, we identi-
fied FOXC1 variants in 2 of 62 participants (3.2%) of the Ital-
ian PCG cohort (Figure 1C and D).
Across both cohorts, we identified predicted pathogenic
FOXC1 variants in 8 of 131 participants (6.1%) who had condi-
tions thatwerenot explainedbyCYP1B1variants, and8of 166
participants (4.8%)when including individualswhose condi-
tions were explained by CYP1B1 variants (Table 1).
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Figure 1. FOXC1Variants AssociatedWith Suspected Primary Congenital Glaucoma (PCG)
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A, Frameshift andmissense variants identified by exome sequencing. B, Exome
sequencing read depth at the FOXC1 locus (chr6:1390204-2679449, hg19) for
participant PCG029 compared with themean read depth across all suspected
PCG samples. C, Multiplex ligation-dependent probe amplification (MLPA) using
probes within FOXC1 (chr6) and on both sex chromosomes. Signal intensity was
measured in duplicate, normalized, and plotted as themean for participant
PCG029 and all other samples processed in the same batch (control
participants). D, Mean coverage across the FOXC1 locus for exomes (gray) and
genomes (black) from the gnomAD release 2.0.2 collection, indicating location
of variants identified by exome (blue fill) or capillary (no fill) sequencing.
Multiplex ligation-dependent probe amplification probe locations are indicated
in red. Most gnomAD exome sequences (approximately 77%) were processed
with the same or similar exome capture kits as those used in the current study
(Agilent SureSelect).
Table 1. Heterozygous FOXC1Variants Identified in Affected Individuals
Proband
Identification
No. Cohort Coordinates (hg19) Method
FOXC1
Complementary
DNAa FOXC1 Protein
PolyPhen 2,
HumVar SIFT
PCG402-IT Italian 6:1611089-1611091 Exome c.409_411del p.(Val137del) NA NA
PCG297-IT Italian 6:1611029-1611029 Capillary c.349delG p.(Asp117ThrfsTer64) NA NA
PCG029 Australian NA Exome c.902-?_1560+?del NA NA NA
PCG033 Australian 6:1611167-1611167 Capillary c.487G>T p.(Glu163Ter) NA NA
PCG057 Australian 6:1611137-1611137 Capillary c.457A>C p.(Thr153Pro) 0.978
(Probably
damaging)
0
(Damaging)
PCG125 Australian 6:1610780-1610789 Capillary c.100_109del10 p.(Gly34ThrfsTer8) NA NA
PCG128 Australian 6:1611398-1611399 Exome c.718_719delCT p.(Leu240ValfsTer65) NA NA
PCG140 Australian 6:1610949-1610949 Exome c.269C>A p.(Ala90Asp) 0.999
(Probably
damaging)
0
(Damaging)
Abbreviations: NA, not available; SIFT, Sorting Intolerant From Tolerant.
a Coordinates of complementary DNA and protein variants are with respect to consensus complementary DNA and amino acid sequences (NM_001453.2 and
NP_001444.2, respectively).
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Clinical Reinvestigation
Having uncovered potentially pathogenic FOXC1 variants, all
probands were reinvestigated for evidence of ocular and sys-
temic features of ARS (Table 2). Family pedigrees were ascer-
tained, with variant segregation testing performed where
possible (Figure 2). Ocular features of the probands and their
examined family members are shown in eFigure in the
Supplement.
Detailed ophthalmological reexamination of participant
PCG402-IT revealed prominent posterior embryotoxon and
PASongonioscopy.25 Facial dysmorphism includeda flat phil-
trum, a flat nasal bridge, a prominent forehead, lateral bushy
eyebrows, hypertelorism, and a thin upper lip. No other sys-
temic featureswerepresent. These features all suggested a re-
vised diagnosis of ARS.
Reviewof the clinical recordsofparticipantPCG297-IT led
to a revised diagnosis of glaucoma with ARA by 1 year of age.
Posterior embryotoxon, PAS, optic disc cupping, and corneal
edema were present in both eyes, with corneal opacity and
sclerocornea in the right eye. Other systemic features associ-
atedwith ARSwere not present, with the exception of poten-
tialmidfacedysmorphism, includinghypertelorism,a thinup-
per lip, a flat philtrum, dysmorphic ears, and lateral bushy
eyebrows with medial flare.
Reviewof participant PCG029did not reveal any anterior
segment anomalies consistent with ARA. Amore detailed ex-
amination by the individual’s current ophthalmologist was
complicated by bilateral corneal opacity, making a formal ex-
clusion of ARA difficult. Possible syndromic associations in-
cluded hydrocephalus and hearing loss. The same FOXC1 de-
letionwasabsent in all familymembers tested (ie, 1 parent and
5 siblings), and although the other parent could not be tested,
this suggested a de novo origin.
For participant PCG033, corneal opacity again compli-
cated detailed anterior segment examination for ARA. Re-
viewof previousmedical records indicated prominent poste-
riorembryotoxonandPAS,withapossible systemicassociation
of hearing loss. Both 1 parent of participant PCG033 and that
parent’s parent were affected by glaucoma, although a de-
tailedmedical history (including ages at diagnosis) could not
be obtained.
The diagnosis for participant PCG057 was revised to ARS
with secondary glaucoma after the referral of 2 of the partici-
pant’s relatives,ofwhom1wasdiagnosedwithARAor theother
Table 2. Clinical Details of the Probands
Proband
Identification
No.
Age at
Diagnosis Diagnosis Ocular Features
Facial
Dysmorphism
Systemic
Features
Best-Corrected
Visual Acuity
Maximum
Intraocular
Pressure
Cup-Disc
Ratio
PCG402-IT 14 y Congenital
glaucoma
Buphthalmos,
posterior
embryotoxon,
peripheral anterior
synechiae,
megalocornea
Yes NA 20/30:20/30 50/50 0.6/0.7
PCG297-IT 1 mo Congenital
glaucoma
Buphthalmos,
posterior
embryotoxon, iris
stromal hypoplasia,
peripheral anteri
or synechiae,
corectopia, corneal
opacity,
megalocornea
Yes NA 20/40:20/30 23/22 0.6/0.3
PCG029 0 y Primary
congenital
glaucoma
Corneal opacity,
nystagmus
NA Hearing loss,
hydrocephalus,
inguinal hernia,
heart murmur
Count
fingers:20/40
22/27 No view
PCG033 1 y Congenital
glaucoma
Posterior
embryotoxon,
peripheral anterior
synechiae, corneal
opacity,
megalocornea
NA Hearing loss,
congenital hip
dislocation
20/200:20/70 30/30 0.9/0.9
PCG057 0 y Primary
congenital
glaucoma
Haab striae, iris
stromal hypoplasia,
corectopia
Yes Short stature 20/40:20/30 48/40 0.6/0.8
PCG125 8 y Primary
congenital
glaucoma
Buphthalmos, Haab
striae, posterior
embryotoxon, iris
stromal hypoplasia,
peripheral anterior
synechiae, corneal
decompensation
Yes Developmental
delay
20/40:20/25 40/30 0.95/0.6
PCG128 0 y Primary
congenital
glaucoma
Buphthalmos, Haab
striae, peripheral
anterior synechiae
Yes Developmental
delay
NA 50/50 0.75/0.8
PCG140 0 y Primary
congenital
glaucoma
Accommodative
esotropia
NA Mitral valve
replacement,
short stature
20/40:20/40 23/21 0.3/0.6
Abbreviation: NA, not applicable.
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was diagnosed with ARS. Participant PCG057 had no dental,
umbilical, or cardiac anomaliesorhearing lossbutwasof short
stature. An additional relative of participant PCG057was ini-
tially diagnosed with juvenile open-angle glaucoma at age 13
years. On reexamination, this relativewas found to have pos-
terior embryotoxon, mild PAS, and hearing loss and so was
given a revised diagnosis of ARS.Midface abnormalitieswere
evident in at least 3 affected family members (including par-
ticipant PCG057). The same FOXC1 variant was present in all
4 affected family members.
Reexamination of the anterior segment of participant
PCG125 was complicated by corneal opacity in the right eye.
After reviewingpast records, participant PCG125was found to
have been diagnosed with ARA at age 8 years. This partici-
pant alsohadmidface abnormalities andmild intellectual dis-
ability. One of this participant’s parents had also been diag-
nosedwithARAat a similar time, and both the parent and the
participant were found to carry the same FOXC1 variant.
Participant PCG128was reexamined several times follow-
ing genetic testing. Apart frommild PAS in the left eye on go-
nioscopy, no features of ARA were evident. Facial dysmor-
phism included a flat nasal bridge andpossible telecanthus or
hypertelorism, but dental, umbilical, and cardiac abnormali-
ties were all absent. There was an extensive history on 1 side
of the family of adult-onset glaucoma, despite that testing of
the parent on that side of the family of PCG128 did not reveal
the sameFOXC1variant as theparticipant. Although theother
parent of PCG128 could not be tested, an absence of reported
glaucomaor features consistentwithARS suggestedadenovo
origin of the FOXC1 variant.
Finally, participantPCG140hadnoevidenceofARAon re-
peated examination (Figure 4). Associated mitral valve dis-
ease and short staturemay be systemicmanifestations of this
individual’s FOXC1 variant. One parent of this individual did
not carry the same FOXC1 variant. Testing of the other parent
was not performed, although family history suggested a de
novo origin of the FOXC1 variant.
Discussion
Among a total of 131 individualswith a suspecteddiagnosis of
PCG not explained by CYP1B1 variants, 8 of the 131 partici-
pants (6.1%) were found to carry a predicted disease-causing
heterozygous variant of FOXC1. Including individuals whose
conditionswere previously explainedbyCYP1B1variants, the
prevalence ofFOXC1variants in individualswith PCG froman
Australian and Italian cohortwas 8of 166participants (4.8%).
The true frequency could indeed be higher, given that MLPA
failed in 11 of the 84 Australian samples and was not per-
formed on any of the Italian PCG cohort samples.
None of the 8 variants described here have been formally
testedat a functional level, althoughmanyare consistentwith
a revised clinical diagnosis ofARAorARS.Novariantwaspre-
sent in the gnomAD database, and 5 were predicted protein-
truncating variants. Both missense variants were predicted
to be deleterious by PolyPhen-2 and Sorting Intolerant From
Tolerant algorithms and were located in the conserved DNA-
binding forkhead domain of FOXC1, while the in-frame dele-
tion removed a highly conserved amino acid.25
Of the 8 probands found to carry potentially pathogenic
FOXC1 variants, 6 were subsequently discovered to have fea-
tures consistentwithARA, eitheron reexaminationor after re-
view of medical records. For the remaining probands, de-
tailedexaminationof theanterior segmentwaseitherhindered
by corneal opacity in 1 person (participant PCG029) or there
was no evidence of ARA after repeated examination (partici-
pant PCG140). At least 4 probands had systemic features con-
sistentwithARS, includinghearing loss, hydrocephalus, short
stature, or congenital heart disease.Developmental delaywas
Figure 2. Segregation of FOXC1Variants
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present in a further 2 probands, although this is not typically
associated with ARS. All 5 of the probands examined for fa-
cial features had some degree of facial dysmorphism consis-
tent with features reported in ARS. Based on their newly as-
certainedgeneticevidence,all8probandswere thereforegiven
a revised diagnosis of ARS.
Axenfeld-Rieger anomaly and Axenfeld-Rieger syn-
drome are rare conditions that can be difficult to diagnose in
children, especially without detailed ophthalmic examina-
tionunder anesthesia.Ocular signs such as posterior embryo-
toxon or PAS may only be visible by gonioscopy,22 and even
then, thesemayonlybecomeapparentwithage.Diagnosismay
also be complicated in adults, particularly if corneal opacity
obscuresathoroughanteriorsegmentexamination.BothPITX2
andFOXC1showphenotypicvariationwithin families, andonly
approximately 30% of individuals with FOXC1 variants have
extraocular features.21When comparedwith PITX2, FOXC1 is
less likely to be associated with more striking systemic fea-
tures, such as dental or umbilical anomalies,20 and is there-
fore more likely to resemble PCG. Systemic features of ARS,
particularly those in FOXC1-associated disease, often be-
comeapparent only later in life (eg, hearing loss, developmen-
tal delay, and short stature), making an accurate diagnosis of
FOXC1-associated ARA or ARS even more challenging. Fur-
thermore,FOXC1variantscanbe inheriteddenovo (aswascon-
firmed in 2 families and suspected in a further 3 participants
in this study),makingclinicaldiagnosismoredifficult thanpro-
bandswithaknownfamilyhistoryofARS(as reported in3pedi-
grees). All of these issues highlight the difficulties in reaching
aprecise clinical diagnosis ofARAorARSat anearly age.These
data show the value of early genetic testing in presentations
of suspected PCG cases and the revision of several diagnoses
as a direct result.
Accurate diagnosis of PCGhas a number of important im-
plications for genetic counseling. Biallelic variants of CYP1B1
are the most common known genetic cause of PCG, account-
ing for 22% of affected individuals in the Australian
population.26Therefore familieswithchildrenaffectedbyPCG
are often counseled for autosomal recessive inheritance.
Revising this diagnosis to ARA or ARS caused by autosomal
dominantFOXC1variants therefore requiresa revisionof coun-
seling: rather than a maximum risk to siblings of 25%, first-
degree relatives of individuals with inherited disease-
causingFOXC1variantshavea riskof 50%forARAand/orARS,
with approximately 50% of these expected to develop glau-
coma. Importantly, in families with de novo inheritance, the
risk of recurrence for siblings of affected individuals is low.
Glaucoma is also not the only concern for a family with ARA;
the presence ofmultiple associated systemic features should
also be closely investigated and managed. Reaching the cor-
rect clinical and genetic diagnosis allows all family members
theopportunity for genetic testing, appropriate referrals to be
made for surveillance andmanagement, anddiscussionof re-
productive options.
Our data support the importance of genetic information
in a clinical context, especially for conditions, such as child-
hood glaucoma, that carry a broad phenotypic spectrum and
genetic heterogeneity. Indeed, one might consider sequenc-
ing not only FOXC1, but all genes associated with childhood
glaucoma. Thismight be achievedwith exome or genome se-
quencing; however, exome sequencing is likely to be less re-
liable, given the uneven capture and coverage of FOXC1 and
the limited ability to detect copy number variations.27 At the
very least, exome and other capture-based sequencing tests
should be interpreted cautiously when excluding variants in
poorly captured genes such as FOXC1.
Limitations
These cohortswerepredominantly of European ancestry, and
these findings may therefore not be generalizable to other
populations, although lower prevalence of FOXC1 variants
hasbeen reported inPCGcohorts fromIndia (0%to2.4%).28,29
Additionally, MLPA failed in 11 of 84 participants from the
Australian cohort, which means that the true prevalence of
FOXC1 variants could be higher.
Conclusions
In summary, our data support theuse ofFOXC1 sequencing as
a diagnostic aid in cases of suspected PCG, although further
replication will be needed to support the future use of such
panels. Timely sequencing has the potential to accelerate di-
agnosis, minimize excessive examinations under anesthesia,
refinegeneticcounseling,guideappropriate therapy,andmaxi-
mize long-term patient benefit.
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